Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1

Liu, Bin; Cai, Lu; Lv, Huiming; Lei, Xia; Zhang, Yajuan; Zhang, Hongxiu; Guan, Yongmei

doi:10.1080/09513590802056995

Cited by 34 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MMP2/TIMP2 ratio was slightly higher in women with PCOS compared with controls, but this difference did not reach statistical significance, whereas a marked difference was observed in MMP9/TIMP1 ratio between groups (Table 3). A similar increased MMP9/ TIMP1 ratio has previously been reported in serum (Liu et al 2008) and follicular fluid (Gomes et al 2011) samples in PCOS patients. Together these observations confirm alteration of MMP9 activity in PCOS patients and, therefore, provide its potential role in the pathogenesis of the disease.…”

Section: Discussionsupporting

confidence: 60%

“…While increased levels of MMP2 and/or MMP9 have shown in PCOS patients (Lewandowski et al 2006, Liu et al 2007, no significant differences have been observed between PCOS and control in the study by Gomes et al (2011), or a reduced MMP9 level has been reported by Diamanti-Kandarakis et al (2008). Similar conflicting results are also available about serum TIMP1 and TIMP2 levels (Lewandowski et al 2006, Liu et al 2008, Gomes et al 2011. In addition, a review of the literature showed that not only is there no consistency in the serum levels of MMP2 and MMP9 but also there is no record of serum MMP9 gelatinase activity.…”

Section: Introductioncontrasting

confidence: 36%

“…Therefore, consistent correlations have not been observed between the concentration of MMP2 or MMP9 and the serum levels of their corresponding tissue inhibitors in previous works. Accordingly, it has shown that there is no synchronized changes between serum MMP9 and TIMP1 (Lewandowski et al 2006, Liu et al 2008, Gomes et al 2011, or the concentration of TIMP2 is not following the alteration in serum level of MMP2 (Lewandowski et al 2006). Likewise, we showed that the concentration of TIMP1 is not correlated to serum MMP9 level.…”

Section: Discussionmentioning

confidence: 51%

“…Although an increased serum level of MMP9 has been reported in some studies (Lewandowski et al 2006, Liu et al 2008, there are also evidences in literature indicating a marked decline (Diamanti-Kandarakis et al 2008) or even no alteration in the plasma MMP9 concentration in PCOS patients (Gomes et al 2011). These conflicting results may indicate that in comparison to the enzymatic activities, the concentration of MMPs may not play a pivotal role in the pathogenesis of PCOS.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS

et al. 2016

View full text Add to dashboard Cite

It is believed that matrix metalloproteinases (MMPs) play important roles in follicular development and pathogenesis of polycystic ovary syndrome (PCOS). However, conflicting results are available about the alteration of MMP2 and MMP9 concentrations or activities in PCOS. In fact, there is no study entirely investigating both concentration and activity of these MMPs and serum levels of their tissue inhibitors TIMP2 and TIMP1, as well as lipocalin-bound form of MMP9 (MMP9/NGAL). Therefore, the thoroughness of previous studies is questionable. This study was conducted to determine circulatory concentration of MMP2, MMP9, MMP9/NGAL complex, TIMP1 and TIMP2 as well as gelatinase activities of MMP2, MMP9 and MMP9/NGAL complex in women with PCOS and controls. Mean age and BMI as well as serum levels of total cholesterol, triacylglycerol, HDL-C, LDL-C, fasting blood sugar (FBS), insulin, estradiol and sex hormone-binding globulin did not differ between groups, whereas a marked decrease in FSH and significant increases in LH, LH/FSH ratio, testosterone and free androgen index were observed. Women with PCOS and controls showed closed concentrations of MMP2, MMP9, MMP9/NGAL, TIMP1 and TIMP2. Gelatinase activity of MMP9 was found significantly higher in PCOS than in controls (64.53G15.32 vs 44.61G18.95 respectively) while patients and healthy subjects showed similar activities of MMP2 and MMP9/NGAL complex. Additionally, PCOS patients showed a higher MMP9/TIMP1 ratio compared with control women. Direct correlations were also observed between circulatory MMP9 level and the concentration and activity of MMP9/NGAL complex. In conclusion, based on the results of present study, we believe that MMP9 may be involved in the pathogenesis of PCOS.Reproduction (2016) 151 305-311

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Introductioncontrasting

confidence: 36%

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS

et al. 2016

View full text Add to dashboard Cite

show abstract

“…6 MMPs and their tissue inhibitors (tissue inhibitors of metalloproteinases, TIMPs) control the site and remodeling of the ovarian tissue, and are associated with a variety of physiological and pathological processes. 7 PCOS is characterized by abnormalities of ovarian tissue degradation and alterations of MMP expression. 8 It was previously demonstrated that serum MMP-9 concentrations and MMP-9/TIMP-1 ratios were significantly higher in women with PCOS than those in systemically healthy women.…”

Section: Introductionmentioning

confidence: 99%

Elevated matrix metalloproteinase-8 in saliva and serum in polycystic ovary syndrome and association with gingival inflammation

et al. 2015

View full text Add to dashboard Cite

This study aimed to investigate the levels of matrix metalloproteinase-8 (MMP-8) and tissue inhibitors of MMP-1 (TIMP-1) in saliva and serum samples of women with polycystic ovary syndrome (PCOS; n = 80) and matched systemically healthy controls (n = 45), with varying degrees of gingival inflammation. Salivary levels of MMP-8 and the MMP-8/TIMP-1 ratio were significantly elevated in women with PCOS, who also exhibited more gingivitis than systemically healthy women. No major changes were observed in salivary TIMP-1 levels with regard to PCOS. Serum levels of MMP-8 and the MMP-8/TIMP-1 ratio were significantly higher in women with PCOS, irrespective of the presence of gingivitis, while there were no differences in TIMP-1 levels. A positive correlation was indicated between probing depth, bleeding on probing, plaque index and salivary or serum MMP-8 levels or MMP-8/TIMP-1 ratio in the case of PCOS, while a negative such correlation was revealed for TIMP-1 in systemically healthy women. Increased levels of MMP-8 in saliva and serum seem to be more pronounced in women with PCOS, and potentiated in the presence of gingival inflammation. Alterations in MMP/TIMP system triggered by local and systemic inflammation may be implicated in the pathogenesis of PCOS, or the deterioration of its clinical presentation.

show abstract

Therapeutics Targeting Matrix Metalloproteinases

Cathcart

Pulkoski‐Gross

Zucker

et al. 2015

Matrix Metalloproteinase Biology

View full text Add to dashboard Cite

Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1

Abstract: Our results raise the possibility that MMPs may be implicated in the pathophysiology of PCOS either by regulating ovarian tissue remodeling or indirectly by facilitating IGF-I bioavailability through proteolysis of IGFBP-1.

Cited by 34 publications

References 18 publications

Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS

Matrix metalloproteinases 2 and 9 and MMP9/NGAL complex activity in women with PCOS

Elevated matrix metalloproteinase-8 in saliva and serum in polycystic ovary syndrome and association with gingival inflammation

Therapeutics Targeting Matrix Metalloproteinases

Contact Info

Product

Resources

About